Europe Smart Inhalers Market

The Europe smart inhalers market is expected to reach US$ 2,129.61 Mn in 2027 from US$ 302.40 Mn in 2018. The market is estimated to grow with a CAGR of 24.9% from 2019-2027.

The growth of the smart inhalers market is driven by the factors such as, growing geriatric population rising prevalence of COPD and asthma, along with rising awareness regarding the medical condition. However, the market is likely to get impacted due to risks associated with cyber threats limited knowledge regarding the use of smart inhalers.

With rapid urbanization there has been growth in various adverse factors that have led to the growth of respiratory diseases across the Europe. Some of the factors leading to growth in the number of asthma and COPD cases across the Europe are rise in air pollution levels and increasing smoking habits.

The rise in air pollution levels has been a matter of rising concern in developed as well as developing economies. As per data published by the World Health Organization (WHO) released during May 2018, 9 out of 10 individuals are believed to breathe air containing high levels of pollutants. Data published by WHO reveals that approximately 7 million people die every year due to exposure to fine particles present in polluted air, which penetrate deep into lungs and the cardiovascular system. This leads to various diseases such as lung cancer, pneumonia, chronic obstructive pulmonary diseases and respiratory infections, among others. Studies reveal, above 90% of air pollution-related deaths worldwide occur in low- and middle-income countries of the Eastern Mediterranean, European regions. According to world health organization (WHO), about 21,000 premature deaths per year in European region because of air pollution like Ozone pollution courses breathe difficulties, triggers asthma symptoms, and causes lung and heart diseases. Additionally increasing indirect effects of air pollution like growing climate change, because of transport is the fastest growing source of fossil-fuel emissions of carbon dioxide (CO2) which is a largest contributor of the climate change. As per data published by World Health Organization (WHO) Some 40 million people in the 115 largest cities in the European Union (EU) are exposed to air exceeding WHO air quality guideline values for at least one pollutant. Children living near roads with heavy-duty vehicle traffic have twice the risk of respiratory problems as those living near less congested streets. Hence, the rising levels of air pollution coupled is anticipated to drive the demand for smart inhalers market during the forecast period.

In 2018, the inhalers segment held a largest market share of the smart inhalers market, by product. The inhalers is expected to dominate its market share in 2027 owing to the increasing mortality rate of asthma. The inhalers segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027.

UK is expected to lead the market in the Europe region because the growing prevalence of asthma and COPD Across the country. According to the data published in Asthma UK, in 2016 to 2017 there were 77,124 admissions to hospital for asthma in the UK and in 2017 1,484 people in the UK died from an asthma attack in the UK. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the Europe region during the forecast period.

Italy Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)

Get more information on this report Request Free Sample PDF

Europe Smart Inhalers Strategic Insights

Strategic insights for the Europe Smart Inhalers provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Smart Inhalers Report Scope

Europe Smart Inhalers Regional Insights

The geographic scope of the Europe Smart Inhalers refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

EUROPE SMART INHALERS - MARKET SEGMENTATION

By Product

• Inhalers
• Nebulizers

By Disorder

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

By End User

• Home-care Settings
• Hospitals & Clinics

By Geography

• Europe

• UK
• Germany
• France
• Spain
• Italy

Company Profiles

• GlaxoSmithKline plc
• Adherium Ltd.
• Vectura Group plc
• Novartis AG
• Findair Sp. z o. o.
• Cohero Health
• Crux Product Design Ltd
• Teva Pharmaceuticals
• 3M
• Amiko Digital Health Limited